NeuroDerm Ltd. (NDRM) announced Monday morning that it will pursue a comparative bioavailability regulatory path for ND0612 based on comparative pharmacokinetic data in place of data from Phase 3 clinical efficacy trials. The decision was made following a meeting with the FDA.
from RTT - Before the Bell http://ift.tt/2h1mfnr
via IFTTT
No comments:
Post a Comment